RESIQUIMOD

Synonym(s):4-Amino-2-(ethoxymethyl)-alpha;alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol;R848;R-848;S28463

CAS NO.：144875-48-9
Empirical Formula: C17H22N4O2
Molecular Weight: 314.38
MDL number: MFCD00937759
SAFETY DATA SHEET (SDS)
Update Date: 2024-04-03 12:01:51

What is RESIQUIMOD?

Description

Resiquimod (CAS 144875-48-9) is a Toll-like receptor 7/8 agonist.1 May be used as an immune adjuvant in cancer vaccines.2 Resiquimod-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.3 Topical treatment of wild-type mice induces systemic autoimmune disease which may be used as a model of systemic Lupus erythematosus.4? It displayed potent antiviral activity (EC50 = 23.5 nM) in a murine norovirus replicon model.5

The Uses of RESIQUIMOD

Resiquimod is an imidazoquinoline derivative that acts as an immune response modifier. Resiquimod shows antitumor and antiviral activity and is used in the treatment of skin lesions such as herpes simplex virus. Resiquimod is a toll-like receptor 9 (TLR7) agonist.

The Uses of RESIQUIMOD

Resiquimod has been used in the stimulation of bone marrow-derived dendritic cells (BMDCs) stimulation( and B cells. It has also been used as a ligand for toll-like receptors (TLR7) in malignant melanoma cell line B16F10.

What are the applications of Application

R-848 is an immune response modifier and TLR7 and TLR8 activator

Definition

ChEBI: Resiquimod is an imidazoquinoline.

Biochem/physiol Actions

Resiquimod belongs to the class of imidazoquinolinamines compounds with immunomodulatory effects. Resiquimod increases the levels of cytokines such as TNF-α, IL-6 and IFN-α.

storage

Store at +4°C

References

1) Jurk et al. (2002), Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848; Nat. Immunol., 3 499 2) Sabado et al. (2015), Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma; Cancer Immunol. Res., 3 278 3) Ilyinskii et al. (2014), Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release; Vaccine, 32 2882 4) Yokogawa et al. (2014), Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erthematosus; Arthritis Rheumatol., 66 694 5) Tuipulotu et al. (2018), TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation; Antimicrob. Agents Chemother., 62 e02417

Properties of RESIQUIMOD

Melting point:	190-193°
Boiling point:	553.6±50.0 °C(Predicted)
Density	1.28
storage temp.	-20°C
solubility	DMSO: soluble10mg/mL, clear (warmed to 60 °C)
form	powder
pka	14.63±0.29(Predicted)
color	white to tan
λmax	325nm(lit.)
Merck	14,8151
Stability:	Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.

Safety information for RESIQUIMOD

Signal word	Danger
Pictogram(s)	Skull and Crossbones Acute Toxicity GHS06 Health Hazard GHS08
GHS Hazard Statements	H301:Acute toxicity,oral H350:Carcinogenicity
Precautionary Statement Codes	P201:Obtain special instructions before use. P202:Do not handle until all safety precautions have been read and understood. P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P270:Do not eat, drink or smoke when using this product. P280:Wear protective gloves/protective clothing/eye protection/face protection. P308+P313:IF exposed or concerned: Get medical advice/attention. P405:Store locked up.